NCT03092635

AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy

Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to look at the effects that the study drug (OPC) has on AGE levels in patients with ER+ metastatic breast cancer.

Detailed description

AGEs are a type of metabolite, or substance, found in the food. The AGE content in food is determined by the types of food you eat and also how you prepare your food. The researchers helping conduct this study have found a potential link between AGE levels and cancer. The purpose of this study is to see if certain drug (OPC) has an effect on the AGE levels in your blood and to see if those AGE levels have an effect on your cancer.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	OPC	OPC is a derivative of grape seed extract

Timeline

• Start date: 2017-06-06
• Primary completion: 2021-11-10
• Completion: 2022-04-22
• First posted: 2017-03-28
• Last updated: 2025-01-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study